US equities
|
SPCX
$147.79
▲+0.00%
TSLA
$373.71
▲+0.00%
MU
$896.07
▲+0.00%
GOOGL
$340.27
▲+0.00%
NVDA
$216.47
▲+0.00%
META
$694.25
▲+0.00%
NFLX
$68.69
▲+0.00%
SNDK
$1,365.38
▲+0.00%
SPCX
$147.79
▲+0.00%
TSLA
$373.71
▲+0.00%
MU
$896.07
▲+0.00%
GOOGL
$340.27
▲+0.00%
NVDA
$216.47
▲+0.00%
META
$694.25
▲+0.00%
NFLX
$68.69
▲+0.00%
SNDK
$1,365.38
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by ProMIS Neurosciences Inc.
< Previous
1
2
Next >
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
October 06, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
September 01, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
August 13, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
August 03, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
July 28, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
July 27, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
July 14, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Participate in Upcoming Conferences in June
May 28, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
May 12, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
March 25, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
March 18, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
January 30, 2026
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
December 18, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
December 10, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
December 01, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
December 01, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Reverse Stock Split
November 24, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
November 12, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 03, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
October 22, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
September 03, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
August 13, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
July 29, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Private Placement Financing
July 28, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Private Placement Financing
July 22, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
July 22, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
July 21, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 17, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
May 12, 2025
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
< Previous
1
2
Next >
